Expanding on previous industry guidance relative to increased clinical trial diversity, while honing more exacting treatments and better ways to fight diseases that have often disproportionately impacted people of color, is a topic being discussed by multidisciplinary public health experts across the nation.This writing draws attention to the African American demographic, which is continually subject to health care disparities. Any glimpses of knowledge or medical discovery that could potentially help to redress harm or reinforce a weakened familial-cultural infrastructure should be emphasized for sanative restoration of the impacted communities. The focus of this writing is the African American cohort and its nexus to Benign Ethnic Neutropenia as the diverse target population of discussion, hoping to convey a harmonized approach in the examination of (1) the African American Benign Ethnic Neutropenia cohort within the context of basic scientific understanding, (2) the interplay of applicable governing regulatory protections, and (3) increased clinical trial participation to enlarge the pathway for increased diversity in clinical trials.

中文翻译：

---

受保护类别、不受保护状况和生物标志物 - 一种用于增加患有良性种族中性粒细胞减少症 (BEN) 的非裔美国受试者临床试验多样性的方法/公式

与增加临床试验多样性相关的先前行业指导的扩展，同时磨练更严格的治疗方法和更好的方法来对抗通常对有色人种影响更大的疾病，这是全国多学科公共卫生专家正在讨论的主题。本文引起了人们的关注非裔美国人人口一直受到医疗保健差异的影响。任何可能有助于纠正伤害或加强薄弱的家庭文化基础设施的知识或医学发现都应该得到重视，以促进受影响社区的健康恢复。本文的重点是非裔美国人群体及其与作为讨论的多样化目标人群的良性种族中性粒细胞减少症的关系，